Novadigm Therapeutics

NovaDigm - Longevity Through Telemedicine

Business Model
B2B
Total Funding
$20.0M
Last Round
$6.0M GrantJun 2017
Rounds
2

About

NovaDigm Therapeutics develops vaccines and immunotherapeutics to protect patients from fungal and bacterial infections that can be recurrent, drug-resistant, and life-threatening. Founding scientists from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center created lead candidate NDV-3/NDV-3A, a recombinant Als3-protein vaccine that showed preclinical cross-kingdom protection against Candida and Staphylococcus aureus, including MRSA. Phase 1 studies in healthy adults found the vaccine safe, well-tolerated, and immunogenic, supporting later trials in recurrent vulvovaginal candidiasis.

Summary

Novadigm Therapeutics is a Biotech company. It has raised $20.0M in total across 2 rounds, most recently a $6.0M Grant round in Jun 2017. Investors include Rusnano.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

GrantJun 2017
$6.0M

Sign up to see all 2 rounds

Series B through Grant — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Novadigm Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/novadigm-therapeutics"><img src="https://indexed.vc/api/badge/company/novadigm-therapeutics" alt="Novadigm Therapeutics on Indexed.vc" width="260" height="76" /></a>